Hyperparathyroidism Drug Profiles and Clinical Trials- Global Trends and Analysis Review, H2 2017
LONDON, Oct. 25, 2017 /PRNewswire/ -- Hyperparathyroidism clinical trials report from VPA Research provides comprehensive analysis and trends in global Hyperparathyroidism disease clinical trials. The research work analyzes the evolution of Hyperparathyroidism clinical trial trends across countries and regions.
Download the full report: https://www.reportbuyer.com/product/5158746
The report focuses on drugs and therapies being evaluated for Hyperparathyroidism treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.
Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner offering quick access to Hyperparathyroidism clinical trials.
Major drugs under development in Hyperparathyroidism are provided in the report along with their details of Mechanism of Action, Route of Administration, Target, therapy, molecule and class.
Scope of the Report-
- Number of Hyperparathyroidism clinical trials across regions- Asia and Oceania, Europe, Middle East Africa and Americas
- Trial information by Phase and Subjects recruited
- Trial information by status, type, sponsor type
- Drugs used for treatment of Hyperparathyroidism
- Both observational and interventional trials analyzed
- Success rates of trials are analyzed
- Trends in enrollment over the past ten years identified
- Leading sponsors of Hyperparathyroidism clinical trials worldwide are listed
Reasons to Buy-
- Track competition and design competitive advantages
- Identify right partners to associate with for further research
- Evaluate potential opportunities available in further clinical trials of the disease
- Formulate business development strategies through success rates of clinical trials
- Identify quick markets for recruiting subjects based on trials count by each market
Executive Summary
Of the four thyroid glands, at least one gland produces more than normal volume of parathyroid hormones. Though the root cause is unknown, hyperparathyroidism occurs when the gland enlarges. This leads to abnormal volume of phosphorous, calcium and vitamin D to move from bones into the blood. Classic symptoms include patients feel tired, irritable and achy, kidney stones, abdominal pain, bone pain and muscle aches. Typically, high calcium levels in blood are diagnosed. Hyperparathyroidism can lead to other medical conditions such as osteoporosis, pancreatic and renal failure.
Types-
- Primary Hyperparathyroidism
- Secondary Hyperparathyroidism
Primary hyperparathyroidism is caused by over stimulation of a normal number of parathyroid cells, the enlarged thyroid gland is removed through surgery in severe cases and in moderate cases, calcium and Vitamin D supplements are suggested.
Secondary hyperparathyroidism on the other hand, develops in response to renal dysfunction, abnormal phosphate levels and Vitamin D. To regulate these functions, high volume of PTH hormones and parathyroid hyperplasia are secreted.
Drugs in Hyperparathyroidism clinical trials-
Alfacalcidol
Amiloride
Asp7991
Bupivacaine Hydrochloride
Calcifediol
Calcitriol
Captopril
Cholecalciferol
Cinacalcet
Cta018(Lunacalcipol)
Darbepoetin Alfa
Denosumab
Dexmedetomidine
Doxercalciferol
Dp001
Eplerenone
Etelcalcetide Hydrochloride
Evocalcet
Furosemide
Hydrochlorothiazide
Lanthanum Carbonate
Lisinopril
Lnp1892
Maxacalcitol
Niacin
Osvaren
Parathyroid Hormone
Paricalcitol
Phoslo(Calcium Acetate)
Sevelamer Carbonate
Valsartan Actavis
Vs 105
Strontium Ranelate
Download the full report: https://www.reportbuyer.com/product/5158746
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
https://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
SOURCE ReportBuyer
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article